title: Keratoconjunctivitis sicca associated with administration of etodolac in dogs: 211 cases (1992-2002).
abstract: OBJECTIVE
  To characterize features and response to treatment of keratoconjunctivitis sicca (KCS) associated with oral administration of etodolac in dogs.
  
  
  METHODS
  Retrospective case series.
  
  
  METHODS
  65 cases obtained from a survey of veterinary ophthalmologists (group A) and 146 cases reported to Fort Dodge Animal Health (group B).
  
  
  METHODS
  Data analyzed included breed, sex, age, weight, dose and duration of etodolac administration, results of Schirmer tear test at the time of diagnosis and last follow-up, treatments, and response to treatments. Groups A and B were analyzed separately by use of forward stepwise logistic regression models developed to predict probability of complete remission or clinical improvement as a function of several variables.
  
  
  RESULTS
  Most dogs developed severe KCS (84 eyes of 50 dogs [group A]; 111 eyes of 62 dogs [group B]). Resolution of KCS occurred in 7 of 65 (A) and 23 of 146 (B) dogs. No response to treatment was observed in 26 of 65 (A) and 27 of 146 (B) dogs. Fifty-one (A) and 52 (B) dogs had records that were sufficiently complete to use in models. In group B, dogs with etodolac treatment intervals < 6 months prior to the onset of KCS were 4.2 times as likely to have remission as were dogs with treatment intervals > or = 6 months.
  
  
  CONCLUSIONS
  Shorter duration of etodolac administration (< 6 months) was associated with improved outcome in 1 population of dogs. Monitoring of tear production should be considered prior to and during administration of etodolac in dogs.
authors.affiliation: Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, USA.
authors.forename: Gia
authors.initials: G
authors.lastname: Klauss
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Giuliano
authors.forename: Cecil P
authors.initials: CP
authors.lastname: Moore
authors.forename: Charles M
authors.initials: CM
authors.lastname: Stuhr
authors.forename: Stacy L
authors.initials: SL
authors.lastname: Martin
authors.forename: Jeff W
authors.initials: JW
authors.lastname: Tyler
authors.forename: Kelsie E
authors.initials: KE
authors.lastname: Fitzgerald
authors.forename: Debra A
authors.initials: DA
authors.lastname: Crawford
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D017308:Etodolac / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D007638:Keratoconjunctivitis Sicca / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D016015:Logistic Models; D008297:Male; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013666:Tears / Q000187:drug effects* / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D017308:Etodolac